Uri Lopatin, MD, is a serial biotech entrepreneur. He co-founded Assembly Pharmaceuticals as the Chief Medical Officer in 2012, and became Chief Medical Officer and Vice President of R&D for Assembly Bio (NASDAQ:ASMB) following the merger of Assembly Pharma with Ventrus Biosciences in 2014. As part of ASMB, he helped raise over $300 million to move their first two generations of novel therapeutics for hepatitis B into global phase 1 and phase 2 clinical studies.
Prior to that, he held clinical and translational science roles at Schering Plough, Roche, and Gilead Sciences, and was a Visiting Partner at Y Combinator. Uri is an infectious disease physician and has published and patented broadly in virology and immunology. He received his training in Internal Medicine at UMDNJ-New Jersey Medical School, University of Washington, NYU Medical Center and fellowship training in Infectious Disease at the National Institutes of Health.
This person is not in the org chart
This person is not in any teams
This person is not in any offices